Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 6/20 | 0.61 |
| ▸ | CES2 | O00748 | 3/20 | 0.54 |
| ▸ | CES1 | P23141 | 3/20 | 0.54 |
| ▸ | GSK3B | P49841 | 12/20 | 0.48 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5190490 | 0.87 | PTPN1 (0.53) | PTPN1CES2CES1GSK3BHCAR1 | |
| SCHEMBL1852011 | 0.86 | GSK3B (0.52) | PTPN1CES2CES1GSK3B | |
| SCHEMBL12876821 | 0.86 | GSK3B (0.52) | PTPN1CES2CES1GSK3BHCAR1 | |
| SCHEMBL865889 | 0.82 | PTPN1 (0.58) | PTPN1CES2CES1GSK3B | |
| SCHEMBL6543881 | 0.82 | GSK3B (0.59) | PTPN1GSK3B | |
| SCHEMBL23360861 | 0.81 | GSK3B (0.56) | PTPN1GSK3B | |
| SCHEMBL10596273 | 0.81 | GSK3B (0.58) | PTPN1GSK3B | |
| SCHEMBL19367869 | 0.80 | CES1 (0.59) | PTPN1CES2CES1HCAR1 | |
| SCHEMBL1849394 | 0.79 | CES2 (0.56) | PTPN1CES2CES1GSK3B | |
| SCHEMBL29520207 | 0.79 | CES2 (0.61) | PTPN1CES2CES1GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 183 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025130765-A1 | COMPOUNDS, COMPOSITIONS AND METHODS THEREOF | HEPAITECH (BEIJING) BIOPHARMA TECHNOLOGY CO., LTD. (CN) | 2025-06-26 | — | — | WO | disclosed |
| WO-2025106362-A1 | RIPK1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2025-05-22 | — | — | WO | disclosed |
| WO-2025066935-A1 | COMPOUNDS, COMPOSITIONS AND METHODS THEREOF | HEPAITECH (BEIJING) BIOPHARMA TECHNOLOGY CO., LTD. (CN) | 2025-04-03 | — | — | WO | disclosed |
| WO-2024174317-A1 | N-PHENYLIMINE-CONTAINING DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | 贵州大学 | 2024-08-29 | — | — | WO | disclosed |
| CN-118164965-A | Pyrimidine-triazole-fluorine substituted phenyl cyclopropylamine derivative and application thereof | 郑州大学 | 2024-06-11 | — | — | CN | disclosed |
| US-11584742-B2 | Substituted aminothiazoles as inhibitors of nucleases | MASARYKOVA UNIVERZITA (CZ) | 2023-02-21 | — | — | US | disclosed |
| US-20220002282-A1 | SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES | MASARYKOVA UNIVERZITA (CZ) | 2022-01-06 | — | — | US | disclosed |
| EP-3556755-B1 | SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES | UNIV MASARYKOVA (CZ) | 2021-11-17 | — | — | EP | disclosed |
| CN-112313229-A | Substituted aminothiazoles as inhibitors of nucleases | 马萨里克大学 | 2021-02-02 | — | — | CN | disclosed |
| US-20200247800-A1 | SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS NADPH OXIDASE INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2020-08-06 | — | — | US | disclosed |
| EP-1001934-A1 | INDOLE COMPOUNDS AS COX-2 INHIBITORS | PFIZER PHARMACEUTICALS INC. (JP) | 2000-05-24 | — | — | EP | disclosed |
| US-6025531-A | REACTING A PROCHIRAL KETONE WITH A MIXTURE BORON-CONTAINING COMPOUNDS HAVING A BORANE REACTION PRODUCT FROM OPTICALLY ACTIVE BETA-AMINOALCOHOL AND A BORON HYDRIDE OR A METAL BOROHYDRIDE, AND AN OPTICALLY ACTIVE OXAZABOROLIDINE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2000-02-15 | — | — | US | disclosed |
| EP-0713848-B1 | Process for producing optically active carbinols | SUMIKA FINE CHEMICALS COMPANY (JP) | 1999-09-08 | — | — | EP | disclosed |
| WO-1999005104-A1 | INDOLE COMPOUNDS AS COX-2 INHIBITORS | PFIZER PHARMACEUTICALS INC. (JP) | 1999-02-04 | — | — | WO | disclosed |
| US-5831132-A | REDUCING AGENT FROM BORANES AND AMINO ALCOHOLS | SUMIKA FINE CHEMICALS COMPANY, LTD. (JP) | 1998-11-03 | — | — | US | disclosed |
| US-5801280-A | Processes for preparing optically active alcohols and optically active amines | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1998-09-01 | — | — | US | disclosed |
| US-5717116-A | TREATING A MIXTURE OF PHENYLHALOGENOMETHYLCARBINOLS WITH A LIPASE IN THE PRESENCE OF A CARBOXYLATE FOLLOWED BY CYCLIZATION WITH A BASE | SUMIKA FINE CHEMICALS COMPANY, LIMITED (JP) | 1998-02-10 | — | — | US | disclosed |
| EP-0736509-A2 | Processes for preparing optically active alcohols and optically active amines | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1996-10-09 | — | — | EP | disclosed |
| EP-0735142-A2 | Process for producing (R)-styrene oxides | SUMIKA FINE CHEMICAL COMPANY, LTD. (JP) | 1996-10-02 | — | — | EP | disclosed |
| EP-0713848-A1 | Process for producing optically active carbinols | SUMIKA FINE CHEMICALS Company, Limited (JP) | 1996-05-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11584742-B2 | Substituted aminothiazoles as inhibitors of nucleases | RNASEH1, DNASE1, FEN1 | PTPN1 3966/4885CES2 3987/4885CES1 3169/4885 |
| US-20200247800-A1 | SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS NADPH OXIDASE INHIBITORS | NOX1, CYBB, NOX4 | PTPN1 674/4885CES2 845/4885CES1 478/4885 |
| US-20220002282-A1 | SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES | RNASEH1, DNASE1, FEN1 | PTPN1 3966/4885CES2 3987/4885CES1 3169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.